AP
ALNY icon

Antipodes Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Antipodes Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.2M Buy
163,533
+18,223
+13% +$5.5M 0.9% 44
2026
Q1 		$48.1M Buy
145,310
+97,424
+203% +$33.2M 0.93% 42
2025
Q4 		$19M Buy
47,886
+15,930
+50% +$7.05M 0.4% 51
2025
Q3 		$14.6M Sell
31,956
-90,848
-74% -$37M 0.33% 50
2025
Q2 		$40M Sell
122,804
-36,750
-23% -$10.2M 1.24% 26
2025
Q1 		$43.1M Buy
159,554
+25,795
+19% +$6.63M 1.35% 24
2024
Q4 		$31.5M Sell
133,759
-5,616
-4% -$1.48M 1.09% 29
2024
Q3 		$38.3M Sell
139,375
-99,121
-42% -$25.8M 1.33% 28
2024
Q2 		$58M Buy
238,496
+32,917
+16% +$5.2M 2.11% 23
2024
Q1 		$30.7M Buy
205,579
+16,438
+9% +$2.74M 0.97% 29
2023
Q4 		$36.2M Buy
189,141
+77,307
+69% +$13.2M 1.13% 28
2023
Q3 		$19.5M Buy
111,834
+111,778
+199,604% +$21.3M 0.63% 33
2023
Q2 		$10K Sell
56
-84
-60% -$16.7K ﹤0.01% 65
2023
Q1 		$28K Buy
140
+22
+19% +$4.62K ﹤0.01% 61
2022
Q4 		$28K Buy
+118
New +$25.2K ﹤0.01% 62

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Antipodes Partners's ALNY Position: Q2 2026 in Review

Antipodes Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q2 2026, buying an estimated $5.5M and bringing the position to 163,533 shares worth $49.2M. The position accounts for 0.9% of the portfolio, ranked #44.

Antipodes Partners first reported a position in ALNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $58M in Q2 2024. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Antipodes Partners held 163,533 shares of Alnylam Pharmaceuticals worth $49.2M as of Q2 2026.
  • Antipodes Partners bought 18,223 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.5M.
  • Alnylam Pharmaceuticals made up 0.9% of Antipodes Partners's portfolio in Q2 2026, its #44 holding.
  • Antipodes Partners first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Antipodes Partners's Alnylam Pharmaceuticals position peaked at $58M in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.